T-knife Therapeutics

📍 San Francisco, United States🗓 Founded 2018👥 91 employees💰 Last funded 2021
Biotechnology Research🌐 t-knife.com
Website LinkedIn
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company’s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in T-knife Therapeutics?
T-knife Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did T-knife Therapeutics last raise funding?
The most recent investment in T-knife Therapeutics recorded on gritt.io was in 2021.
When was T-knife Therapeutics founded?
T-knife Therapeutics was founded in 2018.
What industry is T-knife Therapeutics in?
T-knife Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is T-knife Therapeutics based?
T-knife Therapeutics is headquartered in San Francisco, United States.